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Lack of transparency, wrongdoings, and unlawful promotion characterize the 
healthcare industry; these are especially prevalent within the pharmaceutical 
industry. Consequently, an investigation into the evidence of the corruption and the 
ethical infringement is needed. In this paper, I will evaluate the pharmaceutical 
industry’s adherence to the three major branches of ethics. The ever-increasing 
prices of pharmaceutical products, especially medications used for the combating of 
anaphylaxis and cancer, coupled with the compensatory-based medication 
promotion and research points to a major crisis in the realm of social justice. These 
examples, among many other current issues, lead to difficulties in individuals 
receiving the medications they truly need, either because they cannot afford them or 
the information is being withheld. Recent price hikes in medications also raise 
questions of whether this industry is truly providing for the health needs of all 
individuals or if it is merely preying on profit-generating opportunities. 
 
 Over recent years, the healthcare 
industry has been under fire due to an ever-
increasing realization of their lack of 
transparency, wrongdoings, and unlawful 
promotion – these things are especially 
evident within the pharmaceutical industry. 
The increased realization of corruption in 
this industry may have come about because 
of the increasing prevalence of high-
deductible healthcare plans that allow the 
public greater exposure to the true cost of 
their medications. The astronomical prices 
of pharmaceuticals, especially for 
medications used for combating life-
threatening events such as anaphylaxis and 
cancer, point to a major ethical dilemma as 
they restrict the number of individuals who 
can access the medications they need. 
 Public discontent with the 
pharmaceutical industry may also be due to 
the increasing prevalence of news stories 
that highlight unethical “marketing 
agreements” and the promotion of 
pharmaceuticals that may not even work for 
what they have been prescribed, as well as 
the existence of proprietary partnerships 
between prescribing doctors and 
pharmaceutical companies. This 
combination of occurrences raises questions 
as to whether the industry is truly providing 
for the healthcare needs of all individuals; 
or, perhaps it is merely preying on profit-
generating opportunities. The evident 
corruption surrounding pharmaceutical 
companies and the outlandish prices charged 
for their products warrant an investigation 
into the ethical infringements being made by 
the industry. The claims of corruption 
surrounding the pharmaceutical industry can 
be investigated through an evaluation of 
case studies and a discussion of ethical 
practices of this industry with consideration 
to the ethics, or lack thereof, displayed in the 
case studies. 
 
Case Studies  
 EpiPen Price Increase 
 A major ethical impingement of the 
pharmaceutical industry that has been a 
topic of great debate in recent months is the 
soaring cost of the EpiPen, which has 
undergone a 400% price increase since 
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being acquired by Mylan in 2007. While this 
device was originally developed as a nerve-
gas antidote, it was discovered shortly 
thereafter to be exceedingly valuable as a 
treatment for life-threatening allergic 
reactions.1 The dosage delivery mechanism 
found within the EpiPen has also been 
patented, making it the only immediate 
anaphylactic treatment with the capability to 
calculate the exact dose needed to be 
injected into the victim.2 This patented 
mechanism and the device’s life-saving 
value provide grounds which Mylan can use 
to further increase the price of the device as 
they are able to market this unique, life-
preserving device. However, in the event of 
a life-threatening allergic reaction, two 
EpiPens are needed if the victim has not 
entered medical care within 15 minutes of 
the first dose. Due to not being able to 
predict the situation in which one will be at 
the onset of anaphylaxis, it is imperative that 
two EpiPens are always carried to prevent 
an event more serious than the onset of 
anaphylaxis, doubling the cost of an already 
expensive device so widely needed. For 
families with one or more anaphylactic 
children, an innumerable amount of devices 
are needed so that one is always within 
reach when the victim is exposed to an 
anaphylactic trigger.  
 With the price for a two-pack of 
EpiPens increasing from $57 to $608 in the 
decade that it has been owned by Mylan, the 
outlandish prices for such a crucial 
pharmaceutical are beginning to be felt more 
than ever as greater numbers of Americans 
transition into low-premium, high-
deductible healthcare plans with higher out-
of-pocket costs for prescription medications. 
Many are feeling as though they have no 
choice but to devise a way around the 
pharmaceutical industry to get the protection 
they need by buying pre-filled vials of 
                                                          
1 Rubin, 2016. 
2 Ibid. 
epinephrine inject themselves with, while 
other pharmaceutical industries, such as 
CVS, are attempting to design a product that 
does basically the same thing, but with a 
two-pack cash price a sixth of the cost of the 
Mylan brand.3 This CVS-produced generic 
has been coined Adrenaclick and its 
convenient debut after the outlandish price 
of the Epi-Pen began getting national 
attention begs the question of if CVS is 
marketing this generic because they see a 
widespread need for it or because they saw 
the ability to capitalize on the exposure of 
Mylan’s ridiculous pricing. 
 
 Orphan Drug Act of 1983 
 Another recent event that brings 
ethical practices into question was the 
publishing of an article this February that 
outlines how individuals with rare diseases 
or in low-income brackets are unable to 
obtain the medication required for treatment 
due to exceedingly high prices.4 The 
inability for those individuals with rare 
diseases to obtain the necessary medications 
proves excruciatingly difficult, even under 
the Orphan Drug Act of 1983. The Orphan 
Drug Act was enacted as a way for the 
government to provide incentives in the way 
of tax breaks to companies who have the 
capability to produce a drug needed and 
drive research for rare diseases, such as 
Huntington’s disease or Amyotrophic 
Lateral Sclerosis (ALS), but do not have the 
financial capability to completely fund the 
costs associated with the research and 
development of these drugs. The costs 
associated with the research and 
development of new pharmaceuticals are 
partly due to the Kefauver-Harris 
Amendment, which mandates that 
companies prove the safety and 
effectiveness of pharmaceutical agents 
before marketing begins, setting forth 
3 Pepperman, Westermann-Clark, & Lockey, 2016. 
4 Lathrop, 2017. 
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excruciatingly high standards for which 
drugs in research and development must 
pass. Despite these high standards, the 
number of orphan drugs produced prior to 
the Orphan Drug Act was less than 50 and 
now the number of available over drugs is 
well over 1,000.  
 While the combination of the Orphan 
Drug Act and the Kefauver-Harris 
Amendment have increased the availability 
of drugs for rare diseases as well as the 
safety and effectiveness of these drugs, they 
rarely increase the obtainability of the drugs 
as the resulting prices of drugs developed 
are far beyond the realm of affordability for 
many Americans. The government’s 
jurisdiction in encouraging or regulating the 
production of these Orphan Drugs 
unfortunately does not extend into a 
capability for regulating the market price of 
these pharmaceuticals.5 Since research and 
development far outweigh the potential 
profit from producing an orphan drug and 
the loss is not easily recouped through 
government incentives, pharmaceutical 
companies often charge more than 100 
dollars per pill of an orphan drug. These 
prices often even extend into the several 
hundred dollars per pill range. This is an 
example of the pharmaceutical industry 
capitalizing on human illness. Also, when 
companies partake in these activities, they 
are acting against the Lord and withholding 
these medicines from those who need it 
most.6 
 
 Eli Lilly and Company 
 A final case study on the topic of 
ethical deficiency in the pharmaceutical 
industry arises from a major pharmaceutical 
company, Eli Lilly, whose headquarters are 
in Indianapolis, Indiana. This company 
retains good standing in Indiana regardless 
of their questionable activity since it is often 
                                                          
5 Lichtenburg & Waldfogel, 2003. 
6 Matthew 25:40, New International Version. 
overlooked with a preference for looking 
towards the good this company does in their 
home state. The Lilly Foundation, a division 
of Eli Lilly, strives toward making drastic 
improvements in global health during this 
century and the Lilly Endowment 
Scholarship Program awards almost 150 
Indiana students with a full-ride scholarship 
to an Indiana state university of their choice 
every year. However, in recent years, this 
company has been involved in several 
corrupt acts, with one of the more major 
ones involving charges brought against Eli 
Lilly by the US Securities and Exchange 
Commission, or SEC.  
 Charges brought against Eli Lilly by 
the SEC arose after the discovery of off-
shore “marketing agreements” made by 
subsidiaries of Eli Lilly and involved the 
transfer of large sums of money to off-shore, 
third-party accounts to individuals in Russia, 
Brazil, China, and Poland. The money 
transferred to these accounts was then being 
funneled to government officials to secure 
millions of dollars from the country’s 
pharmaceutical markets.7 During court 
proceedings, it was uncovered that Eli Lilly 
had known about their subsidiaries’ corrupt 
actions and violation of the Foreign Corrupt 
Practices Act, or FCPA, yet chose to not 
take further action. During the same time 
that these charges and the proceedings were 
made public, Eli Lilly released a statement 
that they would be increasing the number of 
scholarships they provide by about 50 per 
year. Whether coincidence or a strategic 
ploy to take attention off their corruption, it 
successfully hid their wrongdoings from 
their immediate community. 
 
Discussion of Ethics 
 A critical evaluation of each of these 
three case studies within the framework of 
the three major forms of normative ethics 
7 “SEC Charges Eli Lilly and Company with FCPA 
Violations,” 2012. 
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first warrants a discussion as to what exactly 
normative ethics are.8 Normative ethics is 
the study of ethical actions and explores the 
way in which humankind ought to act. In 
simpler terms, normative ethics sets forth a 
framework for which actions are right and 
which actions are wrong, both with a sense 
of morality. The three major branches of 
normative ethics are eudaimonism, 
deontology, and consequentialism. Each of 
these branches deal with the determination 
of what is morally right and wrong in 
different ways. These three approaches leave 
out the relatively recent evolutionary ethics, 
but as this field is still developing and pulls 
most its points from the other three forms, 
its absence will not detract much from the 
discussion. The first approach of normative 
ethics to be investigated will be 
eudaimonism, or virtue ethics, which 
focuses largely on social justice. Next, 
deontology, or Kantian ethics, which puts 
forth the notion of universality in 
determining whether an action is good or 
bad. Lastly, discussion will be entered on 
consequentialism, or utilitarian ethics. This 
branch of ethics holds that the determination 
of whether an action is morally good or bad 
lies in whether it maximizes utility.9 
 
 Eudaimonism    
 The first approach of normative 
ethics, eudaimonism, is an approach that 
emphasizes social justice. With the taking of 
the Hippocratic Oath and the integral nature 
of justice within the realm of public health, 
the entire health industry should maintain 
vision on the goal of helping those who need 
it, whether they can afford it or not.10 
Considering the three case studies delineated 
above, it appears that eudaimonism is not 
upheld within the pharmaceutical industry as 
social justice is often pushed aside to make 
way for capitalizing on human illness. 
                                                          
8 O’Toole, 2006. 
9 O’Toole, 2006. 
However, this form of ethics is not action 
guiding, but focuses on the end goal of an 
objective state of happiness with its primary 
concern on the agent’s own character.11 This 
industry continually finds new ways to 
capitalize on those who are in desperate 
need of medication as well as those who are 
incompetent about medications. Through the 
constant seeking for areas where 
capitalization is possible, pharmaceutical 
companies continually disregard the 
adherence to this form of ethics.  
 When CVS produced the 
Adrenaclick in response to the need 
plaguing the market, it is most likely that 
they saw the potential for profit and sprung 
to action. However, CVS could have wanted 
to truly fill a gap in the market to ensure the 
well-being of all those who suffer from life-
threatening allergic reactions. The action 
taken by CVS could fit into the realm of 
eudaimonism and the end-goal of objective 
happiness as it allows for the survival of 
many who would be unable to afford this 
emergency medication otherwise. However, 
in the case of Eli Lilly’s subsidiaries 
securing large portions of the 
pharmaceutical markets in foreign countries 
there is found a major violation of this form 
of ethics as the only benefit to arise from 
their behavior was the accruing of greater 
profits. Without a decrease in the price of 
pharmaceutical agents or increased 
availability, no progress was made toward 
an objective state of happiness as many that 
contain the will to live a full life were still 
unable to get the medications required to 
make their will a possibility. Lastly, in the 
case of the Orphan Drug Act, despite the 
efforts of the government to encourage the 
production of pharmaceutical agents for rare 
disease and the inability of the government 
to regulate the prices a major detraction 
from social justice is felt. If no one can 
10 Gosten & Powers, 2006. 
11 O’Toole, 2006. 
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afford these medications, the individual in 
need is going to be unable to receive the 
medications they need and the company is 
going to be unable to make a profit, in no 
way are they going to add to reaching an 
objective state of happiness. 
 
 Deontology 
 The next approach at ethics is 
deontology, or Kantian ethics, which 
focuses on the only intrinsically good thing 
as being a good will. This branch of ethics 
also puts forth that for an action to be 
permissible, it must be able to be applied to 
all people without contradiction as to if it is 
the right action.12 While this is difficult to 
achieve, there are a few situations that can 
occur within the pharmaceutical industry 
that can be agreed upon as being the wrong 
action. As an example, doctors will 
prescribe medication to patients without 
certainty of its full effect to fulfill an 
agreement with a pharmaceutical or research 
company. This action not only goes against 
the Biblical command to treat others as one 
would want treated, but also impedes upon 
this form of ethics as many medical 
professionals would not want a 
pharmaceutical agent whose complete 
effects are not known to be used on them 
nor would they want to unknowingly be 
used as a subject in a study.13 This approach 
to normative ethics also asserts that humans 
should not be used as means to an end, such 
as profit or an approved drug, because they 
are ends in themselves. Considering this, all 
three of the case studies discussed above 
violate this form of ethics, in some form or 
another, as they strive towards capitalizing 
human illness. 
 
 Consequentialism  
 The last form of normative ethics to 
be discussed is consequentialism, or 
                                                          
12 O’Toole, 2006. 
13 Luke 6:31, New International Version.  
utilitarian ethics. This approach to ethics 
believes that the best action to take is the 
one that maximizes utility, or the sum of all 
pleasure that can be derived from an action, 
to the greatest extent. Consequentialism also 
believes that the consequences of any action 
are the only by which one can measure 
whether it is morally right or wrong.14 
Utilitarianism shifts its focus outward and 
takes other’s interests into account when 
making the decision between right and 
wrong, also, and can often be found being 
applied to social welfare economics and the 
crisis of global poverty. With 
pharmaceutical companies setting outlandish 
prices for medications needed by their 
customers, they are only thinking of 
themselves and recouping their expenditures 
or generating a profit, and are therefore in 
violation of this branch of ethics. This can 
be found to be true of Mylan, in their 400% 
price increase, as well as the astronomical 
prices of the drugs developed under the 
Orphan Drug Act. However, the competition 
provided by these high prices does allow 
space and motivation for the development of 
innovative pharmaceutical agents. 
 Aside from these case studies, a 
major point of concern within the ethical 
practices of the pharmaceutical industry is 
the ability of many powerful pharmaceutical 
firms to influence the research scientists and 
the publications on the medications they 
have developed. When the safety and 
effectiveness research of a pharmaceutical 
agent is funded by the producing company, 
there are three main ways that corruption 
can occur within the research, including the 
conflict of norms and the creation of 
dependency networks.15 While the negative 
influence often occurs as the result of a 
monetary incentive from the pharmaceutical 
industry to the researchers, it could also 
arise from fear of what could happen to the 
14 O’Toole, 2006. 
15 Gray, 2013.  
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research firm should they disprove what the 
company is claiming the drug does.16 This 
inadequacy in disproving those drugs which 
do not work, or the continual occurrence of 
Type I errors in their data, often leads to the 
distribution of misleading information and 
medical practitioners prescribing 
medications that are not the best fit for their 
patients. 
 
Conclusions 
 All of this is not to say that there 
have not been revolutionary advances in the 
ethics of the pharmaceutical industry in the 
recent years. Whether these have come 
about due to the enactment of new 
regulations or to provide better for the 
general welfare of society, they have 
nevertheless occurred. Increased 
transparency to companies’ unethical 
practices for consumers, as well as the 
increasing calls for globalization, has called 
consumers to be more involved in the 
sourcing of their healthcare all-around, 
especially within the pharmaceutical 
industry.17 In the past, there have been cases 
of agreements between prescribing doctors 
and pharmaceutical researchers that have led 
to individuals being prescribed a medication 
that they are not yet sure works. This has 
been mostly eradicated through the 
enactment of the Kefauver-Harris 
Amendment, which demands extensive 
testing to prove the effectiveness and safety 
of each pharmaceutical that is released. 
Introduced in 1981, the International 
Federation of Pharmaceutical Manufacturers 
and Associations, or IFPMA, has been 
devoted to moving the pharmaceutical 
industry to adopt a self-regulatory ethical 
compliance model and increase the number 
of transparent relationships between 
pharmaceutical companies and consumers.18 
The end goal of the initiatives set forth by 
IFPMA is really the ability to provide 
effective care for its patients.  
 While the pharmaceutical industry 
has been under fire within the past several 
years for partaking in unethical behaviors, a 
lack of transparency amid globalization, and 
unlawful promotion and production of 
medications, it is truly in the process of 
minimizing the occurrence of these things. 
The unethical behaviors of the 
pharmaceutical industry are being combated 
through the Orphan Drug Act, despite its 
current shortcomings, the Kefauver-Harris 
amendment, and the work of the 
International Federation of Pharmaceutical 
Manufacturers and Associations. Unlawful 
promotion and production of 
pharmaceuticals is approaching a minimum 
as consumers have begun to take it upon 
themselves to become more informed as to 
the medications they have been prescribed. 
This is especially true through the continual 
technological advances that make almost 
everything accessible at an individual’s 
fingertips. The monopoly held by Mylan 
with the EpiPen is coming to an end as the 
CVS-produced Adrenaclick available for a 
sixth of the cost allows anaphylaxis sufferers 
on low-premium, high-deductible plans to 
obtain a safer method of delivering the 
much-needed combatant into their system 
quickly without the use of a pre-filled 
adrenaline syringe. While there is truth 
behind the claims of corruption surrounding 
the pharmaceutical industry, efforts are 
continually being made to combat this 
corruption and the individuals behind the 
pharmaceutical industry are no less human 
than the rest of mankind are in a continual 
battle with sin, often in the forms of power 
and greed. 
 
                                                          
16 Rodwin, 2013.  
17 Shaw & Whitney, 2016. 
18 Ibid. 
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